PharmaIN Corporation Announces Poster Presentation of Phase 1 PHIN-214 Data in Decompensated Cirrhosis at AASLD’s The Liver Meeting® 2026

Emerging safety, pharmacokinetic, and pharmacodynamic results from the first multiple-ascending dose cohorts of the Phase 1 PHIN-001 study to be presented on November 5.

BOTHELL, Wash., October 1, 2026 —PharmaIN Corporation, a clinical-stage biopharmaceutical company developing novel therapies for advanced liver disease, today announced that new Phase I clinical data from the company’s ongoing PHIN-001 study of PHIN-214, its lead product candidate for decompensated cirrhosis, will be presented in a poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026, being held November 5–9, 2026, in Denver, Colorado.

PHIN-214 is a novel, subcutaneously administered V1a partial agonist designed to reduce portal pressure and improve systemic and renal hemodynamics in patients with decompensated cirrhosis. The poster will present emerging safety, pharmacokinetic, and pharmacodynamic findings from the first cohorts of the ongoing multiple-ascending-dose portion of the Phase 1 PHIN-001 study.

“The presentation of these data at The Liver Meeting, the premier global forum for hepatology, marks an important milestone for the PHIN-214 program,” said Elijah Bolotin, Ph.D., President and Chief Executive Officer of PharmaIN. “We look forward to sharing our findings with the hepatology community and discussing the potential of PHIN-214 as a convenient, subcutaneously administered outpatient therapy to address the significant unmet needs of patients with decompensated cirrhosis.”

Poster presentation details

Abstract Title: EMERGING SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC RESULTS OF THE FIRST MULTIPLE-ASCENDING DOSE COHORT FROM THE PHASE 1 PHIN-001 STUDY OF PHIN-214 IN ADULTS WITH DECOMPENSATED CIRRHOSIS

Authors: Eric Lawitz¹, Tarek Hassanein², Jacqueline O’Leary³, Anita Kohli⁴, Mangesh Pagadala⁵, Ethan Weinberg⁶, Christina C. Lindenmeyer⁷, Gary Reiss⁸, Douglas A. Simonetto⁹

¹Texas Liver Institute, University of Texas Health San Antonio, ²Southern California Research Center, ³Dallas VA Medical Center, ⁴Arizona Liver Health, ⁵The Liver Institute at Methodist Dallas, ⁶University of Pennsylvania, ⁷Cleveland Clinic, ⁸Tandem Clinical Research, ⁹Mayo Clinic Rochester
Abstract number: 1499
Session: Portal Hypertension and Other Complications of Cirrhosis (1450-1688)
Date and time: Thursday, November 5, 2026, 8:00 a.m.–5:00 p.m. MST (presentation time: 12:00–1:00 p.m. MST)
Location: Colorado Convention Center, Denver, Colorado

The poster will be available on the PharmaIN website at www.pharmain.com following the presentation.

About PHIN-214

PHIN-214 is a novel V1a partial agonist and an optimized vasopressor therapy designed to target a clinically validated mechanism of action in portal hypertension. Designed for self-administration by subcutaneous injection, PHIN-214 has the potential to offer a safe and practical outpatient treatment option for the management of complications associated with portal hypertension in patients with decompensated cirrhosis.

PHIN-214 is currently being evaluated in a Phase 1 clinical study in patients with decompensated cirrhosis (NCT05490888).

About PharmaIN Corporation

PharmaIN Corporation, based in Bothell, WA, is a clinical-stage biopharmaceutical company pioneering first- and best-in-class subcutaneous therapies through peptide engineering. By leveraging its expertise in target-specific biology, peptide drug design, and innovative drug delivery, PharmaIN is focused on developing novel treatments for patients with advanced cirrhosis and cancer.

For more information, visit www.pharmain.com.

Media and Investor Contact
BD@pharmain.com